Navigation Links
Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
Date:10/7/2010

BETHESDA, Md., Oct. 7 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 3 study of D-tagatose as a monotherapy in Type 2 diabetes showed a statistically significant (p<0.05) reduction in HbA1c levels of 0.4% at 10 months in relatively healthy people with diabetes (U.S. ITT LOCF, n=101 and Global PP, n=92)*.  The reduction was even more pronounced among PP patients treated in the U.S., and the reduction in HbA1c generally increased over the 10 months patients were treated (see Table 1).

The NEET (Naturlose® Efficacy Evaluation Trial) data show that D-tagatose was more effective in the U.S. population than in the Indian population, as the PP patients in the U.S. who were treated with Dtagatose had a reduction in HbA1c of 0.4% at two months, 0.6% at six months and 1.1% at 10 months on therapy (p<0.05).

Patients in the study had a low average randomization HbA1c of 7.5% globally.  An HbA1c level of 6% or below is considered normal.  An 8% level is considered high. The American Diabetes Association recommends a goal of reducing HbA1c to 7% or below in people with diabetes.

"These are promising results and we are pleased with the significant drop in HbA1c levels among patients treated with Dtagatose.  As a monotherapy in a patient population with mild disease, this achievement is even more compelling," said Dr. Claire Kruger, Chief Executive Officer of Spherix.  "We believe that further development in the Type 2 diabetes indication is merited, and we look forward to engaging a partner to continue this work."

John Amatruda, M.D., a drug-development executive who was
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Spherix Announces Second Quarter 2010 Financial Results
2. Spherix Announces the Closing of $6.3 Million Registered Direct Offering
3. Spherix Announces Results of Annual Shareholders Meeting
4. Spherix Incorporated Announces Annual Shareholders Meeting Date
5. Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development
6. Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Spherix Reports Second Quarter 2009 Earnings
8. Spherix Announces Termination of Arla License Agreement
9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
10. Spherix Regains Full NASDAQ Compliance
11. Spherix to Exhibit at the BIO 2009 International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 ... international investment research firm, announces the initiation ... a French biopharmaceutical company developing and marketing ... care indications.      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... comprehensive report examining the investment merits of ...
(Date:6/18/2013)... 2013  Techne Corporation (NASDAQ: TECH ... to acquire 100% ownership of Bionostics Holdings Limited ... is a global leader in the development, manufacture ... proper operation of in vitro diagnostic ... blood glucose and blood gas testing.  Biosnostics has ...
(Date:6/18/2013)... , June 18, 2013   Lexicon ... a biopharmaceutical company focused on discovering breakthrough treatments ... Northcott has joined the company as its ... Mr. Northcott brings extensive commercial experience to Lexicon, ... a variety of therapeutic areas. Mr. ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Inflamax ... Proof of Concept and Phase I-IV clinical trials, ... alliance with Northern Air Environmental Technologies (NAET), a ... the deployment, monitoring, and servicing of mobile Environmental ... Ocular clinical trials. , Inflamax ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... CLAREMONT, Calif., Oct. 25, 2011 Keck Graduate Institute (KGI) ... speaker at the upcoming Pichia 2012 conference from February 23 ... spent years conducting internationally-renowned research on the development and use ... system for the production of recombinant proteins. At ...
... JUNCTION, N.J., Oct. 25, 2011 Insmed Incorporated (Nasdaq CM: ... Tuesday, November 8 th , 2011, at 8:30 AM ET, ... 2011.  Insmed intends to issue its quarterly financial results press ... To participate in the live conference call, ...
... Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the ... on operations and disclosed the outcome of a strategic ... management and AMT,s Board of Directors that enables the ... development. The CHMP,s recent opinion, while not approving Glybera®, ...
Cached Biology Technology:KGI Professor Cregg to Be Featured Speaker at Pichia 2012 Conference 2Insmed to Host 2011 Third Quarter Earnings Conference Call 2Insmed to Host 2011 Third Quarter Earnings Conference Call 3Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 2Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 3Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline 4
(Date:6/17/2013)... Biochemical and Biophysical Research Communications , Saint Louis ... previously unknown viruses. The technique offers the potential to ... identified a particular virus as the likely source of ... scientists use blood serum as a biological source to ... complete deciphering of the human genome, SLU researchers used ...
(Date:6/17/2013)... bacteria, and algae, is a common component of sugar-free ... the medical field it,s approved by the FDA ... used during surgery as a substance that opens the ... , Now Profs. Ehud Gazit and Daniel Segal of ... and the Sagol School of Neuroscience, along with their ...
(Date:6/17/2013)... CORVALLIS, Ore. Amphibian populations are declining worldwide and ... be spread by bullfrogs, but a two-year study shows ... suggestions that bullfrogs are a tolerant carrier host that ... frogs from eggs in controlled experimental conditions, they found ... dendrobatidis , also called Bd or a chytrid fungus, ...
Breaking Biology News(10 mins):Saint Louis University researchers discover a way to detect new viruses 2Saint Louis University researchers discover a way to detect new viruses 3Artificial sweetener a potential treatment for Parkinson's disease 2Bullfrogs may help spread deadly amphibian fungus, but also die from it 2
... International Scientific Congress attended by more than 2,500 delegates ... The conclusions will be published as a full report ... the Danish Prime Minister Mr. Anders Fogh Rasmussen today. ... Conference in December 2009 and will hand over the ...
... have taken a first look at the broad genetic ... Although scientists have known for more than a century ... are likely to suffer from low reproductive success, the ... still the subject of debate. The new study, ...
... An international research team, involving Professor Rajeev Ahuja at ... to understand the mechanism behind the catalytic effects of ... a synergistic approach and the results, published this week ... Letters , will fasten efforts to develop new catalysts. ...
Cached Biology News:'Climate change: Global risks, challenges and decisions' 2'Climate change: Global risks, challenges and decisions' 3Researchers take first look at the genetic dynamics of inbreeding depression 2Researchers take first look at the genetic dynamics of inbreeding depression 3Revealing new applications for carbon nanomaterials in hydrogen storage 2
... the professional, student, or faculty researcher, the new ... your research and improve the quality of your ... the edge that researchers using LI-COR DNA analysis ... The 4300 System is a third generation instrument ...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... testing at various temperatures, this chamber ... a clean heating unit to maintain ... 140F. Transparent panels allow full visibility, ... access to the work area. Includes ...
... Label IT siRNA Tracker Intracellular Localization ... a straight forward approach to directly ... design, in an efficient yet non-destructive ... Subcellular localization and functional inhibition of ...
Biology Products: